Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
5(55.6%)
Phase 1
4(44.4%)
9Total
Phase 2(5)
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT06335407Phase 1Recruiting

Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study

Role: lead

NCT06679062Phase 2Recruiting

Suvorexant for Treatment of AUD and PTSD

Role: lead

NCT04360681Phase 2Recruiting

Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

Role: lead

NCT06580444Phase 2Not Yet Recruiting

Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study

Role: lead

NCT04331288Phase 1Completed

Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study)

Role: collaborator

NCT04827056Phase 1Completed

Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

Role: lead

NCT03852628Phase 2Terminated

Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD

Role: lead

NCT03376139Phase 2Withdrawn

Zonisamide Outpatient Study

Role: lead

NCT03548714Phase 1Completed

Clinical Trial to Evaluate the Safety of PT150 (Formerly ORG34517) When it is Taken Concurrently With Alcohol

Role: collaborator

All 9 trials loaded